Opinion: Connecticut’s comptroller explains his thinking about GLP-1s for state employees
The state of Connecticut expects to spend more than $30 million on GLP-1s in 2023. Here’s how it’s thinking through the issue.
This article is part of a partnership between First Opinion and Tradeoffs, a podcast exploring our confusing, costly, and often counterintuitive health care system. To learn more about how the high price of this new wave of weight loss drugs is causing employers to confront their attitudes about obesity, listen to a deeper dive from Tradeoffs, and subscribe to never miss an episode.
It seems these days like everyone is talking about Ozempic and Wegovy. These drugs, known formally as GLP-1 medications, are getting a lot of buzz thanks to strong clinical results in reducing obesity.
What's Your Reaction?
